Also found in: Medical, Wikipedia.


 (no͞o′lăs′tə, nyo͞o′-)
A trademark for the drug pegfilgrastim.
References in periodicals archive ?
8% after the company's first Phase 3 study of Rolontis met the primary efficacy endpoint of non-inferiority in duration of severe neutropenia between Rolontis and Neulasta.
As Vice President and General Manager of Amgens Oncology Business Unit, he was responsible for sales and marketing efforts for Aranesp, Neulasta and NEUPOGEN, and led the successful launches of XGEVA and Nplate.
Soft but Reliable Growth: Growth of a number of established products, XGEVA (bone metastases), Prolia (osteoporosis), Nplate (thrombocytopenia), Vectibix (metastatic colorectal cancer), and Sensipar (secondary hyperparathyroidism), should help to offset some of the risk of anticipated branded and biosimilar competition against Neulasta and Epogen and existing competition against Neupogen.
The 50-50joint venture was launched in 1984 to fund the global development of Epogen (epoetin alfa) and, over time, was expanded to include Neupogen (filgrastim), Neulasta (pegfilgrastim), Aranesp (darbepoetin alfa), Nplate (romiplostim) and brodalumab.
Over time, the scope of the collaboration was expanded to include NEUPOGEN (filgrastim), Neulasta (pegfilgrastim), Aranesp (darbepoetin alfa), Nplate (romiplostim) and brodalumab.
Neulasta is one of the most desirable targets for biosimilar development.
Its products include Prolia for osteoporosis, Enbrel for rheumatoid arthritis and skin disorders, and Neulasta and Neupogen for fighting infection in cancer patients.
Neupogen and Neulasta, two products that stimulate production of white blood cells had sales of $4.
Neulasta and NEUPOGEN sales increased 12 percent to $1,021 million in the fourth quarter of 2011 versus $914 million in the fourth quarter of 2010, primarily driven by an increase in the average net sales price, and to a lesser extent, favorable changes in wholesaler inventories.
Amgen said sales of its drugs Neulasta and Neupogen, which are used to prevent infections in chemotherapy patients, rose 2% to $1.
In 2007, five therapeutic recombinant proteins drove Amgen's success: Enbrel, Epogen, Aranesp, Neupogen and Neulasta.
Its products include Epogen, Aranesp, Neulasta, Neupogen and Enbrel.